US FDA inspection at Tarapur API facility ends with 3 observations

Regulatory & Legal View source PDF Explain this filing

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.7%Reaction day

₹1454.80

prior close

₹1434.90

announcement price

In-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%-1.1% vs market

Pharmaceuticals peers, median of 156sector-0.2%-0.4% vs sector

On the reaction day the stock moved 1.1 pts less than Nifty Midcap 150 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.4

10m

+1.4

15m

+1.5

30m

+1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.7+0.4-1.1-0.2-0.4

Next day

-2.0-1.3-0.7-2.3+0.3

-0.4-0.9+0.6-1.6+1.2

+0.2-1.9+2.0-1.9+2.0

+1.8-1.0+2.8-1.6+3.4

+0.4+0.1+0.3-1.1+1.5

-1.9-0.7-1.2-1.6-0.3

15d

-1.1-0.1-1.0-1.9+0.8

-3.1+2.0-5.1-0.4-2.7

-1.4-0.9-0.6-5.5+4.1

+2.9-3.6+6.5-8.9+11.8

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

US FDA inspected IPCA's API manufacturing facility at Tarapur, Maharashtra from 1 to 5 December 2025. At the end of the inspection, the FDA issued a Form 483 with 3 observations. The company will submit a detailed response to the FDA within the stipulated time and will work to resolve the issues quickly. IPCA said it takes quality and compliance seriously across all its plants.

Likely market impact

Form 483 with 3 observations is relatively minor; near-term stock reaction may be muted but resolution pace will be watched.